<DOC>
	<DOCNO>NCT03039842</DOCNO>
	<brief_summary>This research clinical trial double-blind , stratify randomize , parallel group , two-centre study . It conduct total 250~300 male female subject Department Psychiatry National Cheng Kung University Hospital . Eligible subject psychiatric out- in-patients , age 18~65 year old , psychiatric evaluation clinically suspect bipolar II disorder fulfill inclusion exclusion criterion . The add-on double-blind study treatment dextromethorphan/place commence randomization patient continue open-label valproate . Subjects enrol 12 week double-blind add-on treatment randomly assign ( 1 ) 30mg dextromethorphan+valproate , ( 2 ) 5mg memantine+valproate , ( 3 ) dextromethorphan+memantine+valproate ( 4 ) placebo+valproate . Concomitant benzodiazepine medication ( preferably 8mg lorazepam ) may use daytime sedation , agitation insomnia study . For consideration less influence immune-system , resperidone 1-3mg/daily fluoxetine maximum 20mg/daily chose . We measure treatment response side effect clarify curative effect DM memantine add-on therapy valproate treatment bipolar disorder . This study perform investigate possibly significant beneficial effect subtypes bipolar disorder psychopathology .</brief_summary>
	<brief_title>Combination Dextromethorphan Memantine Treating Bipolar Disorder</brief_title>
	<detailed_description>A total 250~300 male female subject Department Psychiatry National Cheng Kung University Hospital . Eligible subject age 18~65 year old clinically suspect bipolar II disorder invite . The add-on double-blind study treatment dextromethorphan/place commence randomization patient continue open-label valproate . Subjects enrol 12 week double-blind add-on treatment randomly assign ( 1 ) 30mg dextromethorphan+valproate , ( 2 ) 5mg memantine+valproate , ( 3 ) dextromethorphan+memantine+valproate ( 4 ) placebo+valproate . Concomitant benzodiazepine medication ( preferably 8mg lorazepam ) may use daytime sedation , agitation insomnia study . For consideration less influence immune-system , resperidone 1-3mg/daily fluoxetine maximum 20mg/daily chose . We measure treatment response side effect clarify curative effect DM memantine add-on therapy valproate treatment bipolar disorder . This study perform investigate possibly significant beneficial effect subtypes bipolar disorder psychopathology .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Bipolar Disorder</mesh_term>
	<mesh_term>Dextromethorphan</mesh_term>
	<mesh_term>Memantine</mesh_term>
	<mesh_term>Valproic Acid</mesh_term>
	<criteria>A 2day minimum hypomania diagnose bipolar II disorder A total Hamilton Rating Scale Depression score least 18 Young Mania Rating Scale score least 14 screening stage Must allow ensure acceptable compliance visit Pregnant females nurse Women childbearing potential use adequate contraception Received dextromethorphan , memantine , antiinflammatory medication within 1 week prior Clinically significant medical condition ( cardiac , hepatic renal disease ) Received electroconvulsive therapy patient within 4 week prior first dose doubleblind medication Increase total SGOT , SGPT , BUN creatinine 3X upper limit normal .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>dextromethorphan ; memantine ; treatment response</keyword>
</DOC>